These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 38729429)

  • 21. The tumour suppressor SOX11 is associated with improved survival among high grade epithelial ovarian cancers and is regulated by reversible promoter methylation.
    Sernbo S; Gustavsson E; Brennan DJ; Gallagher WM; Rexhepaj E; Rydnert F; Jirström K; Borrebaeck CA; Ek S
    BMC Cancer; 2011 Sep; 11():405. PubMed ID: 21943380
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinicopathological features of women with epithelial ovarian cancer and double heterozygosity for BRCA1 and BRCA2: A systematic review and case report analysis.
    Le Page C; Rahimi K; Rodrigues M; Heinzelmann-Schwarz V; Recio N; Tommasi S; Bataillon G; Portelance L; Golmard L; Meunier L; Tonin PN; Gotlieb W; Yasmeen A; Ray-Coquard I; Labidi-Galy SI; Provencher D; Mes-Masson AM
    Gynecol Oncol; 2020 Feb; 156(2):377-386. PubMed ID: 31753525
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical characteristics of ovarian cancer classified by BRCA1, BRCA2, and RAD51C status.
    Cunningham JM; Cicek MS; Larson NB; Davila J; Wang C; Larson MC; Song H; Dicks EM; Harrington P; Wick M; Winterhoff BJ; Hamidi H; Konecny GE; Chien J; Bibikova M; Fan JB; Kalli KR; Lindor NM; Fridley BL; Pharoah PP; Goode EL
    Sci Rep; 2014 Feb; 4():4026. PubMed ID: 24504028
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevalence and clinical characterization of BRCA1 and BRCA2 mutations in Korean patients with epithelial ovarian cancer.
    Paik ES; Heo EJ; Choi CH; Kim JH; Kim JW; Kim YM; Park SY; Lee JW; Kim JW; Kim BG
    Cancer Sci; 2021 Dec; 112(12):5055-5067. PubMed ID: 34657357
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinicopathological characterization of a real-world multicenter cohort of endometrioid ovarian carcinoma: Analysis of the French national ESME-Unicancer database.
    De Nonneville A; Zemmour C; Frank S; Joly F; Ray-Coquard I; Costaz H; Classe JM; Floquet A; De la Motte Rouge T; Colombo PE; Sauterey B; Leblanc E; Pomel C; Marchal F; Barranger E; Savoye AM; Guillemet C; Petit T; Pautier P; Rouzier R; Gladieff L; Simon G; Courtinard C; Sabatier R
    Gynecol Oncol; 2021 Oct; 163(1):64-71. PubMed ID: 34294414
    [TBL] [Abstract][Full Text] [Related]  

  • 26. BRCA Methylation Testing Identifies a Subset of Ovarian Carcinomas without Germline Variants That Can Benefit from PARP Inhibitor.
    Sahnane N; Carnevali I; Formenti G; Casarin J; Facchi S; Bombelli R; Di Lauro E; Memoli D; Salvati A; Rizzo F; Sessa F; Tibiletti MG
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33352687
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fifteen-year survival of invasive epithelial ovarian cancer in women with BRCA1/2 mutations - the National Israeli Study of Ovarian Cancer.
    Lavie O; Chetrit A; Novikov I; Sadetzki S;
    Gynecol Oncol; 2019 May; 153(2):320-325. PubMed ID: 30872026
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Promoter Hypermethylation of FANCF and Susceptibility and Prognosis of Epithelial Ovarian Cancer.
    Ding JJ; Wang G; Shi WX; Zhou HH; Zhao EF
    Reprod Sci; 2016 Jan; 23(1):24-30. PubMed ID: 26507869
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Is the Homologous Recombination Repair Mutation Defined by a 15-Gene Panel Associated with the Prognosis of Epithelial Ovarian Cancer?
    Liu Y; Chen X; Lu H; Wu X; Liu X; Xu F; Ye D; Ding B; Lu X; Qiu L; Zhu J; Wang Y; Huang X; Shen Z; Zhu T; Shen Y; Zhou Y
    Mol Diagn Ther; 2024 Sep; 28(5):621-632. PubMed ID: 38967864
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The performance of BRCA1 immunohistochemistry for detecting germline, somatic, and epigenetic BRCA1 loss in high-grade serous ovarian cancer.
    Meisel JL; Hyman DM; Garg K; Zhou Q; Dao F; Bisogna M; Gao J; Schultz ND; Grisham RN; Phillips M; Iasonos A; Kauff ND; Levine DA; Soslow RA; Spriggs DR
    Ann Oncol; 2014 Dec; 25(12):2372-2378. PubMed ID: 25281711
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Association between single nucleotide polymorphism of BARD1 gene and BRCA1 gene mutation in epithelial ovarian cancer].
    Liu WL; Zhao JZ; Wang ZZ; Dong B; Hou YY; Wu XX; Guo YJ
    Zhonghua Fu Chan Ke Za Zhi; 2017 Jun; 52(6):403-410. PubMed ID: 28647964
    [No Abstract]   [Full Text] [Related]  

  • 32. Epigenetic Inactivation of BRCA1 Through Promoter Hypermethylation and Its Clinical Importance in Triple-Negative Breast Cancer.
    Yamashita N; Tokunaga E; Kitao H; Hitchins M; Inoue Y; Tanaka K; Hisamatsu Y; Taketani K; Akiyoshi S; Okada S; Oda Y; Saeki H; Oki E; Maehara Y
    Clin Breast Cancer; 2015 Dec; 15(6):498-504. PubMed ID: 26195437
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevalence of germline pathogenic
    Morgan RD; Burghel GJ; Flaum N; Bulman M; Clamp AR; Hasan J; Mitchell CL; Schlecht H; Woodward ER; Lallo FI; Crosbie EJ; Edmondson RJ; Wallace AJ; Jayson GC; Evans DGR
    J Med Genet; 2019 May; 56(5):301-307. PubMed ID: 30683677
    [TBL] [Abstract][Full Text] [Related]  

  • 34. BRCA1 promoter hypermethylation on circulating tumor DNA correlates with improved survival of patients with ovarian cancer.
    Elazezy M; Prieske K; Kluwe L; Oliveira-Ferrer L; Peine S; Müller V; Woelber L; Schmalfeldt B; Pantel K; Joosse SA
    Mol Oncol; 2021 Dec; 15(12):3615-3625. PubMed ID: 34601813
    [TBL] [Abstract][Full Text] [Related]  

  • 35.
    Kraya AA; Maxwell KN; Eiva MA; Wubbenhorst B; Pluta J; Feldman M; Nayak A; Powell DJ; Domchek SM; Vonderheide RH; Nathanson KL
    JCO Precis Oncol; 2022 Feb; 6():e2100159. PubMed ID: 35201851
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Methylation of BRCA1 promoter region is associated with unfavorable prognosis in women with early-stage breast cancer.
    Hsu NC; Huang YF; Yokoyama KK; Chu PY; Chen FM; Hou MF
    PLoS One; 2013; 8(2):e56256. PubMed ID: 23405268
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Outcome of ovarian cancer after breast cancer in BRCA1 and BRCA2 mutation carriers.
    Zaaijer LH; van Doorn HC; Mourits MJ; van Beurden M; de Hullu JA; Adank MA; van Lonkhuijzen LR; Vasen HF; Slangen BF; Gaarenstroom KN; Zweemer RP; Vencken PM; Seynaeve C; Kriege M
    Br J Cancer; 2016 Nov; 115(10):1174-1178. PubMed ID: 27755534
    [TBL] [Abstract][Full Text] [Related]  

  • 38. BRCA1/2 mutations and expression: response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer.
    Dann RB; DeLoia JA; Timms KM; Zorn KK; Potter J; Flake DD; Lanchbury JS; Krivak TC
    Gynecol Oncol; 2012 Jun; 125(3):677-82. PubMed ID: 22406760
    [TBL] [Abstract][Full Text] [Related]  

  • 39. DNA hypomethylation-mediated activation of Cancer/Testis Antigen 45 (CT45) genes is associated with disease progression and reduced survival in epithelial ovarian cancer.
    Zhang W; Barger CJ; Link PA; Mhawech-Fauceglia P; Miller A; Akers SN; Odunsi K; Karpf AR
    Epigenetics; 2015; 10(8):736-48. PubMed ID: 26098711
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characteristics and outcome of BRCA mutated epithelial ovarian cancer patients in Italy: A retrospective multicenter study (MITO 21).
    Artioli G; Giannone G; Valabrega G; Maggiorotto F; Genta S; Pignata S; Lorusso D; Cormio G; Scalone S; Nicoletto MO; Greco F; Rossi E; Spagnoletti I; De Giorgi U; Orditura M; Mosconi AM; Kardhashi A; Bogliolo S; Borgato L
    Gynecol Oncol; 2021 Jun; 161(3):755-761. PubMed ID: 33888336
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.